Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
8
×
boston blog main
clinical trials
san francisco top stories
boston top stories
fda
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
drugs
national
pfizer
boston
cancer
celgene
deals
genentech
intercept pharmaceuticals
investing
merck
What
approved
8
×
drug
fda
medicine
bio
data
disease
fatty
known
liver
nash
new
news
pharmaceuticals
roundup
therapeutics
time
treat
adu
affects
afternoon
agency
ago
aimmune
allergy
alnylam
alnylam’s
americans
approval
awarded
battle
beats
bids
biogen
cancer
cannabis
companies
complicated
date
deeper
Language
unset
Current search:
approved
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug